

Fig 1 The structure of the Vaccibody.




Fig 2 Principle.

3/25

BEST AVAILABLE COPY




Fig 3 Flow cytometry of splenocytes




Fig 4 The NIP-specific control Vaccibodies exhibits binding to the hapten NIP.

5/25




Fig 5 The Vaccibodies exhibit binding to DNP, hence the antigenic scFv is correctly folded.

6/25




Fig 6 APC pulsed with titrated amounts of MHC class II specific Vaccibodies

7/25





Fig 7 The MHC class II-specific Vaccibodies induce a strong anti-Id Ab response in the absence of adjuvants.

A Short hinge



B long hinge




Fig 8 Construction of the two hinge-C γ 3 variants of hIgG3 origin by PCR.

9/25




Fig 9 Construction of the hinge-C γ 3 segments derived from mIgG2b.

10/25




Fig 10 Construction of the scFv derived from the myeloma protein M315.

11/25




Fig 11 Joining of the hinge-Cy3 segments and the M315 scFv by PCR soeing.




Fig 12 Subcloning of the hinge-C γ 3-M315 scFv into pUC19.




Fig 13 Removal of two inconvenient BamHI restriction enzyme sites by QuickChange PCR.




Fig 14 Introduction of stop codon, a SfiI and a BamHI restriction enzyme site downstream of the coding region by QuickChange PCR.




Fig 15 Subcloning into the C cassette of the expression vector pLNOH₂ on HindII-BamHI




Fig 16 Cloning of the V regions specific for NIP and MHCII and assembling into a scFv format by PCR soeing.




Fig 17 Subcloning into the expression vector pLNOH₂ on BsmI/MunI and BsiWI




Fig 18 The final Vaccibody construct.

19/25




Fig 19 The Vaccibody gene construct




Fig 20 Vaccibodies are secreted as functional molecules.

21/25




Fig 21 Production of Vaccibodies by intramucular injection of naked DNA plasmids followed by *in vivo* electroporation

22/25




Fig 22 Tumor avoidance.

23/25




Fig 23 Induction of protective immunity against the MOPC315.4 plasmacytoma.




Fig 24 Level of M315 myeloma protein in sera of mice on a) day 18 and b) day 24 after MOPC315.4 challenge.

25/25




Fig 25 Chemokine Vaccibodies are secreted as functional molecules.